Impact of Cirrhosis on Health-Related Quality of Life and Activity Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in France, Italy, Germany, and Canada
Author(s)
Jens U Marquardt, MD, PhD1, Giada Sebastiani, MD, PhD2, Riku Ota, MPH3, Eliza Smith, MBiochem (Hons)4, Kathryn Tebbs, MSc4, Emily Quinones, BSc (Hons)4, Hayley Wallinger, BSc (Hons)4, Elisabetta Bugianesi, MD, PhD5.
1University of Lübeck, Lübeck, Germany, 2McGill University, Montreal, QC, Canada, 3Global Payer Evidence Lead, Novo Nordisk, Søborg, Denmark, 4Adelphi Real World, Bollington, United Kingdom, 5Department of Medical Sciences, University of Torino, Torino, Italy.
1University of Lübeck, Lübeck, Germany, 2McGill University, Montreal, QC, Canada, 3Global Payer Evidence Lead, Novo Nordisk, Søborg, Denmark, 4Adelphi Real World, Bollington, United Kingdom, 5Department of Medical Sciences, University of Torino, Torino, Italy.
Presentation Documents
OBJECTIVES: Development of liver cirrhosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) has a significant impact on outcomes and may predispose liver failure and cancer. As patient-reported data are limited, we aimed to describe the impact of cirrhosis on activity and health related quality of life (HRQoL) in patients with MASH.
METHODS: Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and their patients with MASH in France, Germany, Italy, and Canada from January-June 2024. Physicians reported patient demographics and presence of cirrhosis. Patients self-reported HRQoL via the NASH-CHECK and EQ-5D-5L (German tariff). NASH-CHECK scores range from 0 (least) to 10 (most impact). EQ-5D-5L utility scores range from 0-1 and Visual Analogue Scale (VAS) scores range from 0-100%; higher scores indicate better HRQoL for both. Patients with physician-reported presence of cirrhosis (CP) were compared using pairwise statistics against patients without physician-reported cirrhosis (NCP) control group after entropy balancing on patient age and sex.
RESULTS: Overall, 247 physicians reported data for 2675 patients, of whom 831 self-reported data. For CP (n=105) and NCP (n=1823), respectively, mean ± standard deviation patient age was 63.5±10.3 and 55.3±11.3; 40.0% and 39.4% were female and mean BMI 34.6±8.4kg/m2 and 32.4±6.5kg/m2 (p≤0.05). Of patients which self-reported data (n=27 and n=598, CP and NCP respectively), mean EQ-5D-5L utility scores were lower for CP (0.77±0.14) than NCP patients (0.86±0.16; p<0.001). VAS scores were also lower (48.2%±20.3% vs 67.5%±18.8%; p<0.001). CP patients reported lower HRQoL in eight of the nine NASH-CHECK domains than NCP, mostly in Activity Limitations Scale (4.5±2.1 vs 2.4±1.9; p<0.001), Fatigue (5.4±2.9 vs 2.6±2.4; p<0.001) and Abdominal Bloating (4.2±2.3 vs 2.2±2.2; p<0.001) domains.
CONCLUSIONS: Presence of cirrhosis decreased HRQoL and impacted daily activities, highlighting the need for improved management strategies in these patients.
METHODS: Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and their patients with MASH in France, Germany, Italy, and Canada from January-June 2024. Physicians reported patient demographics and presence of cirrhosis. Patients self-reported HRQoL via the NASH-CHECK and EQ-5D-5L (German tariff). NASH-CHECK scores range from 0 (least) to 10 (most impact). EQ-5D-5L utility scores range from 0-1 and Visual Analogue Scale (VAS) scores range from 0-100%; higher scores indicate better HRQoL for both. Patients with physician-reported presence of cirrhosis (CP) were compared using pairwise statistics against patients without physician-reported cirrhosis (NCP) control group after entropy balancing on patient age and sex.
RESULTS: Overall, 247 physicians reported data for 2675 patients, of whom 831 self-reported data. For CP (n=105) and NCP (n=1823), respectively, mean ± standard deviation patient age was 63.5±10.3 and 55.3±11.3; 40.0% and 39.4% were female and mean BMI 34.6±8.4kg/m2 and 32.4±6.5kg/m2 (p≤0.05). Of patients which self-reported data (n=27 and n=598, CP and NCP respectively), mean EQ-5D-5L utility scores were lower for CP (0.77±0.14) than NCP patients (0.86±0.16; p<0.001). VAS scores were also lower (48.2%±20.3% vs 67.5%±18.8%; p<0.001). CP patients reported lower HRQoL in eight of the nine NASH-CHECK domains than NCP, mostly in Activity Limitations Scale (4.5±2.1 vs 2.4±1.9; p<0.001), Fatigue (5.4±2.9 vs 2.6±2.4; p<0.001) and Abdominal Bloating (4.2±2.3 vs 2.2±2.2; p<0.001) domains.
CONCLUSIONS: Presence of cirrhosis decreased HRQoL and impacted daily activities, highlighting the need for improved management strategies in these patients.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR197
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Gastrointestinal Disorders